申请人:SPOFA
Spojené Podniky Pro Zdravotnickou Vyrobu
公开号:EP0232435A2
公开(公告)日:1987-08-19
Novel peptide analogs of the serum thymic factor are structurally modified, in comparison with the natural substance, both in their N-terminal and C-terminal parts and inside the amino-acid sequence. They correspond to the general formula I
in which A is pGlu, Gin, Ala-Lys-Ser, pGlu-Ala-Lys-Ser or Gln-Ala-Lys-Ser, B and C are Gly, Phe, Leu, Ala or a direct bond and R is H, an alkyl with 1 to 6 carbon atoms or a 2-phenylethyl.
Dependently on their chemical structure, the subject thymic factor analogs, possess either agonistic (im- munostimulative) or antagonistic (immunosuppressory) properties.
与天然物质相比,血清胸腺因子的新型多肽类似物在 N 端和 C 端以及氨基酸序列内部都进行了结构调整。它们符合通式 I
其中 A 为 pGlu、Gin、Ala-Lys-Ser、pGlu-Ala-Lys-Ser 或 Gln-Ala-Lys-Ser,B 和 C 为 Gly、Phe、Leu、Ala 或直接键,R 为 H、1-6 个碳原子的烷基或 2-苯基乙基。
胸腺因子类似物具有激动(刺激)或拮抗(免疫抑制)特性,这取决于它们的化学结构。